Literature DB >> 7351000

Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan).

J Pedersen-Bjergaard, N I Nissen, H M Sørensen, K Hou-Jensen, M S Larsen, P Ernst, J Ersbøl, S Knudtzon, C Rose.   

Abstract

Acute non-lymphocytic leukemia occurred in eight women following long-term treatment with Treosulfan (= dihydroxybusulfan) for ovarian carcinoma. The leukemia developed from 21 to 58 months (median 50 months) after the institution of chemotherapy. At the time when the leukemia appeared seven of the patients were in complete, and one in partial, remission as regards the ovarian carcinoma. Seven of the eight cases of acute leukemia occurred in a series of 553 patients treated with Treosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient-years up to February 1978. As compared with an expected number of 0.04 cases of acute myeloblastic leukemia based on patient-years, the observed seven cases correspond to a 175-times increased risk. Although the cumulative probability of acute non-lymphocytic leukemia among surviving patients at five years using life-table statistics was 7.6%, the survival curve for the 553 patients with ovarian carcinoma was only slightly affected by death from leukemia. The probability of developing acute leukemia in this study was not significantly correlated to the total cumulative dosage of Treosulfan. Cytogenetic studies of the bone marrow performed after the development of acute leukemia showed chromosome abnormalities in all five patients examined, with hypodiploidy and loss of B and C group chromosomes.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351000     DOI: 10.1002/1097-0142(19800101)45:1<19::aid-cncr2820450106>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  The use of treosulfan and gemcitabine in the treatment of platinum-resistant ovarian cancer.

Authors:  S Hilman; P K Koh; S Collins; R Allerton
Journal:  Oncol Lett       Date:  2010-01-01       Impact factor: 2.967

2.  Chronic myelocytic leukemia as a secondary malignant condition in a patient receiving prolonged chemotherapy for ovarian carcinoma.

Authors:  M Markman
Journal:  West J Med       Date:  1985-08

3.  Therapy-related acute nonlymphocytic leukemia: clinical aspects.

Authors:  J Pedersen-Bjergaard
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

4.  The carcinogenic potential of cytotoxic chemotherapy and its implications for therapeutic decision-making.

Authors:  S K Carter
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 5.  Depressed immunity and the development of cancer.

Authors:  I Penn
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

6.  Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.

Authors:  Y Seto; H Nagawa; M Mori; T Tsuruo; T Muto
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

7.  Endometrial cancer due to busulfan therapy. Report of two cases.

Authors:  M Aksoy; S Erdem; I Bakioğlu; G Dincol
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

Review 8.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

9.  Acute monocytic leukemia complicating combined-modality therapy for localized childhood Ewing's sarcoma.

Authors:  A Schmitt-Gräff; H Jürgens; U Göbel; J Ritter; A Lübbesmeier; F Borchard
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

Review 10.  The process of leukemogenesis.

Authors:  R D Irons; W S Stillman
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.